Jeanne Cabeza1, Patricia J García2, Eddy Segura1, Pedro García3, Francisco Escudero4, Sayda La Rosa2, Segundo León5, Jeffrey D Klausner1. 1. Department of Medicine/Division of Infectious Diseases, UCLA Geffen School of Medicine, Los Angeles, California, USA. 2. Unit of Epidemiology, STD and HIV, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru. 3. Instituto Nacional Materno Perinatal, Lima, Peru. 4. Hospital Nacional Arzobispo Loayza, Lima, Peru. 5. Department of Global Health, University of Washington, Seattle, Washington, USA Instituto de Medicina Tropical, Universidad Mayor de San Marcos, Lima, Peru.
Abstract
OBJECTIVES: Chlamydia trachomatis, which is asymptomatic in most women, causes significant adverse effects for pregnant women and neonates. No programmes conduct antenatal screening in Latin America. We determined chlamydia prevalence, feasibility and acceptability of chlamydia screening, and adherence to treatment in pregnant women in two urban public hospitals in Lima, Peru. METHODS: We offered chlamydia screening using self-collected vaginal swabs to pregnant women ≥ 16 years of age during their first antenatal visit. Chlamydia-infected women were contacted within 14 days and asked to bring partners for counselling and directly observed therapy with oral azithromycin. Unaccompanied women received counselling, directly observed therapy, and azithromycin to take to partners. Test of cure was performed ≥ 3 weeks after treatment. RESULTS: We approached 640 women for the study and enrolled 600 (93.8%). Median age was 27.3 years (range 16-47), median lifetime partners 2.3 (range 1-50), and median gestational age 26.1 weeks (range 4-41). Chlamydia prevalence was 10% (95% CI 7.7% to 12.7%). Of 60 infected patients, 59 (98%) were treated with one dose of azithromycin. Fifty-two of 59 (88%) returned for test of cure, all of whom were treated successfully, with 46 (86%) achieving negative test of cure with one dose of azithromycin, and 6 (12%) after retreatment with a second dose. CONCLUSIONS: C. trachomatis screening and treatment in pregnancy was feasible and highly acceptable in two urban hospitals in Peru. Chlamydia prevalence was high. Clinical trials to evaluate efficacy and cost-effectiveness of chlamydia screening, and treatment of pregnant women to prevent adverse pregnancy outcomes in low-resource settings, are warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES:Chlamydia trachomatis, which is asymptomatic in most women, causes significant adverse effects for pregnant women and neonates. No programmes conduct antenatal screening in Latin America. We determined chlamydia prevalence, feasibility and acceptability of chlamydia screening, and adherence to treatment in pregnant women in two urban public hospitals in Lima, Peru. METHODS: We offered chlamydia screening using self-collected vaginal swabs to pregnant women ≥ 16 years of age during their first antenatal visit. Chlamydia-infectedwomen were contacted within 14 days and asked to bring partners for counselling and directly observed therapy with oral azithromycin. Unaccompanied women received counselling, directly observed therapy, and azithromycin to take to partners. Test of cure was performed ≥ 3 weeks after treatment. RESULTS: We approached 640 women for the study and enrolled 600 (93.8%). Median age was 27.3 years (range 16-47), median lifetime partners 2.3 (range 1-50), and median gestational age 26.1 weeks (range 4-41). Chlamydia prevalence was 10% (95% CI 7.7% to 12.7%). Of 60 infectedpatients, 59 (98%) were treated with one dose of azithromycin. Fifty-two of 59 (88%) returned for test of cure, all of whom were treated successfully, with 46 (86%) achieving negative test of cure with one dose of azithromycin, and 6 (12%) after retreatment with a second dose. CONCLUSIONS:C. trachomatis screening and treatment in pregnancy was feasible and highly acceptable in two urban hospitals in Peru. Chlamydia prevalence was high. Clinical trials to evaluate efficacy and cost-effectiveness of chlamydia screening, and treatment of pregnant women to prevent adverse pregnancy outcomes in low-resource settings, are warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Susan A Wang; John R Papp; Walter E Stamm; Rosanna W Peeling; David H Martin; King K Holmes Journal: J Infect Dis Date: 2005-02-11 Impact factor: 5.226
Authors: W L Whittington; C Kent; P Kissinger; M K Oh; J D Fortenberry; S E Hillis; B Litchfield; G A Bolan; M E St Louis; T A Farley; H H Handsfield Journal: Sex Transm Dis Date: 2001-02 Impact factor: 2.830
Authors: James A Williams; Susan Ofner; Byron E Batteiger; J Dennis Fortenberry; Barbara Van Der Pol Journal: Sex Transm Dis Date: 2014-03 Impact factor: 2.830
Authors: Nazmul Alam; Eric Chamot; Sten H Vermund; Kim Streatfield; Sibylle Kristensen Journal: BMC Public Health Date: 2010-01-18 Impact factor: 3.295
Authors: Kathleen J Paul; Pedro J Garcia; Ann E Giesel; King K Holmes; Jane E Hitti Journal: J Womens Health (Larchmt) Date: 2009-09 Impact factor: 2.681
Authors: Chelsea Lee Shannon; Claire Bristow; Nicole Hoff; Adriane Wynn; Minh Nguyen; Andrew Medina-Marino; Jeanne Cabeza; Anne Rimoin; Jeffrey D Klausner Journal: Sex Transm Dis Date: 2018-10 Impact factor: 2.830
Authors: Claire C Bristow; Patricia Mathelier; Oksana Ocheretina; Daphne Benoit; Jean W Pape; Adriane Wynn; Jeffrey D Klausner Journal: Int J STD AIDS Date: 2017-01-29 Impact factor: 1.359
Authors: Gweneth B Lazenby; Jeffrey E Korte; Sarah Tillman; Florence K Brown; David E Soper Journal: Int J STD AIDS Date: 2016-11-18 Impact factor: 1.359